Free Trial
→ Millionaire warns: Move your money now (From Brownstone Research) (Ad)tc pixel
NASDAQ:PMCB

Nuvilex 8/13/2024 Earnings Report

Nuvilex logo
$0.80 +0.11 (+15.12%)
As of 12:55 PM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Nuvilex EPS Results

Actual EPS
-$0.85
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Nuvilex Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Nuvilex Announcement Details

Quarter
Date
8/13/2024
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Nuvilex's next earnings date is estimated for Wednesday, July 1, 2026, based on past reporting schedules.

Conference Call Resources

Nuvilex Earnings Headlines

Nuvilex (NASDAQ:PMCB) Trading Down 3.6% - Here's Why
May 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30760962
PharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency Applications
September 2, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250902025594/en/pharmacyte-biotech-inc.-increases-stake-in-tnf-pharmaceuticals-around-recent-license-for-breakthrough-light-speed-computing-platform-for-use-in-cryptocurrency-applications/
BSEM: From OTC to Nasdaq Contender!
BioStem Technologies (OTC: BSEM) has posted seven consecutive profitable quarters and just released audited financials for 2024 and 2025 - a key step toward its Nasdaq uplisting. The company paired that move with a $40 million acquisition expanding its reach into hospitals and surgical centers, all within a $300M-plus addressable market. Zacks carries a $25.50 price target on the stock.tc pixel
May 12 at 1:00 AM  |  Huge Alerts (Ad)
PharmaCyte Biotech, Inc. Announces Closing of $7 Million Financing
August 20, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250820055624/en/PharmaCyte-Biotech-Inc.-Announces-Closing-of-7-Million-Financing/
PharmaCyte Biotech, Inc. Announces $7 Million Capital Raise Led by Existing Investors
August 18, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250818528622/en/pharmacyte-biotech-inc.-announces-7-million-capital-raise-led-by-existing-investors/
MyMD Pharmaceuticals Secures Strategic Investments
May 21, 2024  |  businesswire.comhttps://www.businesswire.com/news/home/20240521024499/en/mymd-pharmaceuticals-secures-strategic-investments/
See More Nuvilex Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nuvilex? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nuvilex and other key companies, straight to your email.

About Nuvilex

PharmaCyte Biotech, Inc., a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex (NASDAQ:PMCB), Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.

View Nuvilex Profile
Earnings Tools